ArticleResearch in pharmaceutical sciences2025
Article in Research in pharmaceutical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Effects ofAnimals : an open access journal from MDPI · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Ha-rak (HR), an equal-proportion combination of roots from Experimental approach: The biological activities (anti-allergic, anti-inflammatory, and anti-microbial activities and cell viability) of ethanolic extracts of plants and their combinations in various proportions were evaluated, as well as the chemical content of the developed remedies using the HPLC technique. Findings/Results: HMB-123 was the most significantly effective combination for AD. HMB-123 reduced β-hexosaminidase release from RBL-2H3 cells to a greater extent than chlorpheniramine. HMB-123 significantly inhibited nitric oxide and TNF-α production in LPS-stimulated RAW 264.7 cells. HMB-123 demonstrated antibacterial activity against all tested bacteria and antifungal activity against Conclusion and implications: The combined extracts showed potential as an optimized remedy for AD. HMB-123 demonstrated the highest anti-allergic, anti-inflammatory, and antimicrobial activities, making it a promising development candidate for AD treatment. To confirm safety and efficacy, further pre-clinical and clinical testing is necessary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.